arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

NovoCure Ltd

NVCR
$16.38 ▲ +0.71 (+4.53%) at close
Healthcare ·Surgical & Medical Instruments & Apparatus ·USSurgical & Medical Instruments & Apparatus
14 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
25
Health
Poor
Bearish
auto_awesome

Analytical Summary

NovoCure Ltd faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $1.8B
Dividend Yield
Revenue Growth 8.3%
Op. Margin -23.5%
ROIC -28.7%
FCF / Share $-0.68
Trailing P/E
Price / Book 5.4x
FCF Yield
Debt / Equity 0.57
info Valuation on last close. End-of-day price, Aug 7, 2026.

14-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$655.35M
↑ +8.3%
Net Income Profit after all expenses
$-136.23M
↑ +19.2%
Operating Margin Operating profit as % of sales
-23.5%
↑ +16.7% 9th
FCF / Share Free cash flow per share
$-0.68
↓ -5.8%
Long-Term Debt Long-term obligations
$195.05M
↑ +100.5%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
10
Returns
19
Financial Health
40
Cash Quality
42

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 14 years · 51 quarters